Hemolytic uremic syndrome recurrence after renal transplantation
- 6 August 2008
- journal article
- Published by Wiley in Pediatric Transplantation
- Vol. 12 (6), 619-629
- https://doi.org/10.1111/j.1399-3046.2008.00910.x
Abstract
About 60% of non-Stx-associated aHUS are due to the defect of protection of endothelial cells from complement activation, secondary to mutations in the genes of CFH, MCP, IF, BF, or C3. In addition, 10% of patients have anti-CFH antibodies. While the risk of post-transplant recurrence is less than 1% in Stx-HUS patients, it is approximately 80% in CFH or IF-mutated patients, 20% in MCP-mutated patients, and 30% in patients with no mutation. Patients with anti-CFH antibodies probably also are at risk of recurrence. While MCP-mutated patients can reasonably go to transplantation, recent reports suggest that plasmatherapy started before surgery and maintained life-long may prevent recurrence in CFH-mutated patients. Four successful liver–kidney transplantation utilizing plasmatherapy in CFH-mutated children have been reported recently. In summary, the risk of post-transplant recurrence can now be approached according to genotype. Therefore, aHUS patients should undergo complement determination, screening for anti-CFH antibodies, and genotyping before transplantation. Kidney or kidney + liver transplantation with concomitant plasmatherapy need to be evaluated by prospective trials in patients with hereditary complement abnormalities.Keywords
This publication has 53 references indexed in Scilit:
- Membrane cofactor protein mutations in atypical hemolytic uremic syndrome (aHUS), fatal Stx-HUS, C3 glomerulonephritis, and the HELLP syndromeBlood, 2008
- Ocular involvement in hemolytic uremic syndrome due to factor H deficiency—are there therapeutic consequences?Pediatric Nephrology, 2007
- Complement factor H and the hemolytic uremic syndromeThe Journal of Experimental Medicine, 2007
- Deletion of Complement Factor H–Related Genes CFHR1 and CFHR3 Is Associated with Atypical Hemolytic Uremic SyndromePLoS Genetics, 2007
- Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndromeProceedings of the National Academy of Sciences, 2007
- Secondary failure of plasma therapy in factor H deficiencyPediatric Nephrology, 2006
- Atypical Haemolytic Uraemic Syndrome Associated with a Hybrid Complement GenePLoS Medicine, 2006
- Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcomeBlood, 2006
- The risk of recurrence of hemolytic uremic syndrome after renal transplantation in childrenPediatric Nephrology, 2003
- Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantationPediatric Nephrology, 2002